Biotechnology Taxation Law In Ukraine.

1. Introduction

Biotechnology taxation law in Ukraine concerns the taxation of businesses, research institutions, pharmaceutical manufacturers, biotechnology startups, genetic engineering companies, agricultural biotechnology enterprises, and organisations involved in the development and commercialisation of biological products.

Ukraine does not have one separate, comprehensive statute called the Biotechnology Taxation Act. Instead, biotechnology taxation is governed by a combination of:

The Tax Code of Ukraine 2010.

The Customs Code of Ukraine 2012.

The Law of Ukraine on State Regulation of Activities in the Field of Genetically Modified Organisms.

The Law on Medicinal Products.

The Law on Scientific and Scientific-Technical Activities.

The Law on State Support for Investment Projects with Significant Investments.

Intellectual property and technology-transfer legislation.

General corporate, VAT, customs, employment and international tax rules.

The central legal issue is how Ukraine taxes scientific research, biotechnology production, imports of laboratory equipment, pharmaceutical products, intellectual property, research grants, clinical trials and cross-border biotechnology transactions.

The legal framework must also be understood in the context of Ukraine's European integration and its efforts to harmonise biotechnology, pharmaceutical and tax regulation with European Union standards.

2. Constitutional and Legislative Framework

The Ukrainian Constitution provides the foundation for taxation.

Article 67 of the Constitution establishes the obligation of individuals to pay taxes and levies in accordance with the procedure and amounts prescribed by law.

Article 92 provides that the taxation system, taxes and levies must be established by Ukrainian legislation.

These provisions are important for biotechnology businesses because tax liabilities cannot be created merely through administrative practice or informal regulatory guidance.

The principal legislation is the Tax Code of Ukraine.

It regulates:

Corporate income taxation.

Value-added tax (VAT).

Personal income taxation.

Taxation of royalties and intellectual property.

Transfer pricing.

Tax administration and audits.

Tax penalties and appeals.

International taxation and double-taxation relief.

Legal principle: Biotechnology companies are generally subject to ordinary business taxation unless a specific statutory exemption, reduced rate or preferential regime applies.

3. Corporate Income Taxation of Biotechnology Companies

Corporate income tax is one of the principal taxes affecting biotechnology enterprises in Ukraine.

Under Article 136 of the Tax Code, the general corporate income tax rate is 18%, subject to applicable special regimes and statutory exceptions.

It generally applies to:

Pharmaceutical manufacturing companies.

Biotechnology research and development companies.

Genetic engineering businesses.

Vaccine manufacturers.

Biopharmaceutical laboratories.

Agricultural biotechnology enterprises.

Commercial organisations licensing biological technologies.

A. Taxation of biotechnology profits

A biotechnology company calculates its taxable financial result under the applicable accounting and tax rules.

For example, a Ukrainian biotechnology company may earn revenue from:

Developing vaccines.

Manufacturing biological medicines.

Licensing genetic engineering technology.

Selling laboratory-developed diagnostic products.

Providing contract research services.

Commercialising patented biotechnology inventions.

Its taxable profit is generally calculated by starting with accounting financial results and applying the tax adjustments prescribed by the Tax Code.

B. Research and development expenditure

Research and development is particularly important in biotechnology because the development of a new medicine or biological product can involve substantial expenditure.

Typical expenditure includes:

Laboratory salaries.

Clinical research costs.

Genetic sequencing.

Laboratory equipment.

Biological sample testing.

Research materials.

Scientific software.

Regulatory testing.

Contract research organisation fees.

These expenses may be recognised in accounting and tax calculations subject to the applicable statutory requirements.

However, Ukraine should not be assumed to provide a universal biotechnology R&D tax credit. The deductibility of an expense depends on its accounting treatment, documentation, business purpose and the applicable Tax Code provisions.

C. Capital expenditure and depreciation

Biotechnology businesses frequently invest in expensive assets, including:

DNA sequencing machines.

Bioreactors.

Laboratory automation equipment.

Cold-storage facilities.

Pharmaceutical production machinery.

Diagnostic equipment.

The tax treatment depends on whether the expenditure qualifies as a capital asset or an ordinary business expense.

Where an asset is capitalised, depreciation and applicable tax adjustments must be considered under the Tax Code.

Legal significance: Incorrectly treating capital equipment as an immediate operating expense can create tax disputes, additional tax assessments and penalties.

4. Value Added Tax (VAT) and Biotechnology Products

VAT is particularly important in biotechnology because companies frequently manufacture, import and distribute medicines, medical devices, vaccines and laboratory products.

Ukraine generally applies a standard VAT rate of 20%.

However, qualifying medicines and medical devices may benefit from a reduced VAT rate of 7%.

Article 193.1(c) of the Tax Code establishes the reduced rate for specified categories of medicines and medical devices.

A. Pharmaceutical biotechnology products

The 7% VAT rate may apply to medicines that:

Are authorised for production and use in Ukraine.

Are included in the State Register of Medicinal Products.

For qualifying medical devices, the applicable registration or conformity-assessment requirements must also be satisfied.

The reduced rate is not automatically available to every product manufactured by a biotechnology company.

For example:

ProductGeneral VAT treatment
Registered biotechnology medicine7%, subject to statutory conditions
Qualifying medical device7%, subject to statutory conditions
Unregistered medicinal productGenerally 20%
Ordinary laboratory chemicalsGenerally 20%
General biotechnology consultancyGenerally 20%
Qualifying clinical-trial medicines and devices7%, subject to statutory conditions

The Ukrainian State Tax Service has expressly explained the conditions for applying the 7% VAT rate to medicines and medical devices.

tax.gov.ua+1

 

B. Clinical-trial taxation

Clinical trials involve pharmaceutical companies, hospitals, research institutions and contract research organisations.

Under Article 193.1(c), the reduced VAT rate can also apply to qualifying medicines, medical devices and medical equipment approved for use in authorised clinical trials.

The relevant approval must be obtained from the competent Ukrainian health authority.

A biotechnology company therefore needs to distinguish between:

The supply of qualifying trial medicines.

The supply of ordinary laboratory consumables.

Research consultancy services.

Clinical-trial management services.

Hospital and medical services.

These transactions may have different VAT treatments.

C. VAT exemption and special-purpose medical equipment

Certain medical products may qualify for temporary or special statutory VAT exemptions.

However, the exemption must be interpreted according to its precise legislative conditions.

A product's medical character alone does not establish an entitlement to exemption.

This issue is especially important for biotechnology companies supplying ventilators, diagnostic equipment, biological testing systems and medical devices to hospitals.

5. Customs Duties and Imported Biotechnology Equipment

Ukraine's Customs Code regulates the importation and exportation of biotechnology-related products.

Biotechnology companies frequently import:

DNA sequencing equipment.

Laboratory instruments.

Biological reagents.

Genetic testing materials.

Vaccines.

Pharmaceutical ingredients.

Clinical-trial products.

Research microorganisms.

Medical devices.

The customs treatment depends on tariff classification, customs value, country of origin, intended use and any applicable exemption.

A. Customs valuation

Customs valuation is important where biotechnology companies import specialised equipment from foreign manufacturers.

The customs value generally forms the basis for calculating applicable import duties and import VAT.

Disputes may arise concerning:

The declared transaction value.

Royalty payments.

Related-party transactions.

Freight and insurance costs.

Research equipment supplied without ordinary commercial payment.

Transfer pricing and customs valuation differences.

B. Importation of research materials

Importing genetically modified organisms and biological materials requires particular attention.

The legal treatment depends on the type of organism, intended purpose, risk classification and applicable permits.

Ukraine's Law No. 3339-IX of 23 August 2023 establishes the framework for regulating genetic engineering activities and controlling the market placement of genetically modified organisms and products.

The new law became effective on 16 September 2026, replacing the previous GMO biosafety framework.

zakon.rada.gov.ua+2

 

This is important for biotechnology taxation because customs clearance and the commercial use of imported biological materials may depend on regulatory authorisation.

6. Intellectual Property Taxation in Biotechnology

Intellectual property is a major economic asset for biotechnology enterprises.

It may include:

Patents for pharmaceutical inventions.

Genetic engineering technologies.

Biotechnology manufacturing processes.

Research discoveries.

Diagnostic technologies.

Industrial biological processes.

Software used in biological research.

Licensing rights over patented inventions.

The taxation of intellectual property depends on the nature of the transaction and the legal status of the parties.

A. Royalty taxation

Where a biotechnology company licenses a patented invention to another business, royalty payments may arise.

For example, a Ukrainian company may license a vaccine-production process to a foreign pharmaceutical manufacturer.

The tax treatment may involve:

Corporate income tax.

Withholding tax on payments to non-residents.

VAT, depending on the place-of-supply rules.

Transfer-pricing requirements where applicable.

Double-taxation treaty provisions.

B. Biotechnology patent transfers

Where a company sells or transfers a patent, the transaction must be distinguished from a licensing arrangement.

The sale of intellectual property rights may have different accounting and tax consequences from recurring royalty payments.

The agreement should clearly identify:

Ownership of the invention.

Scope of transferred rights.

Territorial limitations.

Duration of the licence.

Royalty calculation.

Responsibility for patent maintenance.

Rights over future improvements.

C. Cross-border biotechnology licensing

Cross-border biotechnology agreements may involve companies in Ukraine, Germany, the United States, Switzerland and other jurisdictions.

The Ukrainian tax authorities may examine whether payments are genuine royalties, technical-service fees or another form of business income.

Correct contractual classification is therefore essential.

7. Taxation of Biotechnology Research Grants and Government Funding

Biotechnology research frequently receives financial support from government programmes, universities, international organisations and private foundations.

Funding may be used for:

Vaccine research.

Agricultural biotechnology.

Medical genomics.

Stem-cell research.

Biological safety.

Pharmaceutical innovation.

Scientific infrastructure.

Development of diagnostic products.

The tax treatment depends on the legal form of funding.

A. Research grants

A grant is not automatically tax-exempt merely because it supports scientific research.

The following matters must be examined:

Identity of the grant provider.

Legal status of the recipient.

Whether the payment is a grant or contractual consideration.

Restrictions on the use of funds.

Whether the recipient must provide services in exchange.

Applicable statutory exemptions.

B. Government support

Ukraine has legislation supporting scientific and technological development and investment.

Nevertheless, biotechnology companies should not assume that every government subsidy or innovation grant automatically creates a tax exemption.

The particular programme and applicable tax provisions must be examined.

C. International research funding

Where Ukrainian institutions receive funding from international organisations or foreign universities, additional issues may arise concerning:

Tax residency.

VAT on services.

Withholding tax.

Grant reporting.

Currency transactions.

Permanent establishment.

Double-taxation agreements.

A clear grant agreement and separate accounting records are important for demonstrating the correct tax treatment.

8. Transfer Pricing and International Biotechnology Transactions

Transfer pricing is relevant where Ukrainian biotechnology companies conduct transactions with related foreign companies.

Examples include:

A Ukrainian pharmaceutical subsidiary purchasing research materials from its parent company.

A Ukrainian biotechnology company licensing patents from a foreign affiliate.

A multinational pharmaceutical group transferring biological manufacturing technology.

A foreign biotechnology company paying a Ukrainian laboratory for research services.

Related companies exchanging genetic testing technologies.

The Tax Code's transfer-pricing provisions, particularly Articles 39 and related rules, seek to ensure that controlled transactions comply with the arm's-length principle.

A. Arm's-length principle

The prices charged between associated enterprises should generally correspond to prices that independent parties would agree under comparable circumstances.

For biotechnology, this can be difficult because many products are unique.

For example, a newly developed gene-editing process may have no directly comparable market transaction.

Relevant valuation considerations include:

Patent ownership.

Research and development contributions.

Commercial risks.

Manufacturing capabilities.

Regulatory approval.

Expected future revenue.

Geographic licensing rights.

B. Tax avoidance and artificial transactions

Tax authorities may investigate transactions involving:

Artificial royalty payments.

Inflated research-service charges.

Unsubstantiated consulting expenses.

Transfer of patents at undervalued prices.

Profit shifting to low-tax jurisdictions.

Artificially created research expenses.

Biotechnology businesses should retain scientific, accounting and contractual documentation to demonstrate the commercial substance of transactions.

9. Employment and Personal Income Tax in Biotechnology

Biotechnology companies employ scientists, medical researchers, genetic engineers, pharmacists, laboratory technicians and clinical-trial specialists.

Their remuneration is subject to the ordinary Ukrainian employment-tax framework.

The principal obligations include:

A. Personal income tax (PIT)

The general personal income tax rate is 18%, subject to applicable exceptions.

B. Military levy

The military levy is an additional tax obligation. Its applicable rate depends on the taxpayer category and the legislation in force during the relevant period.

C. Unified social contribution (USC)

Employers generally pay unified social contribution on eligible employee remuneration. The ordinary employer rate is 22%, subject to statutory exceptions and special rules.

These obligations apply to biotechnology companies in the same general manner as to other employers.

Example

A biotechnology company employing genetic researchers must:

Calculate employee remuneration.

Withhold applicable personal income tax.

Withhold the applicable military levy.

Pay employer social contributions.

Submit required tax and employment reports.

Failure to fulfil these obligations may result in additional assessments and financial penalties.

10. GMO Taxation and Agricultural Biotechnology

Agricultural biotechnology is particularly important in Ukraine because agriculture is a major part of the national economy.

The sector includes:

Genetically modified seeds.

Agricultural microorganisms.

Biological fertilisers.

Biopesticides.

Genetic crop development.

Plant biotechnology.

Animal biotechnology.

The taxation of these activities depends on the nature of the business and the product.

A. GMO registration and taxation

GMO registration is primarily a regulatory requirement rather than a tax exemption.

The 2023 GMO law, Law No. 3339-IX, provides a new framework for genetic engineering activities and market control.

As of September 2026, the framework is in force. The government has also developed implementing measures, including procedures for GMO registration and risk assessment.

Cabinet of Ministers of Ukraine+1

 

B. Agricultural enterprises

Qualifying agricultural businesses may fall under special tax arrangements, depending on their activities and satisfaction of statutory eligibility conditions.

However, a biotechnology enterprise does not automatically qualify for agricultural tax treatment simply because it develops agricultural technology.

Its actual business activity, income composition and statutory status must be examined.

C. Import restrictions and customs compliance

The new GMO framework also affects the movement of biological materials across Ukrainian borders.

For example, the WTO has recorded restrictions relating to certain GMO imports and transit under the new Ukrainian legislation.

WTO Quantitative Restrictions+2

 

These requirements can affect the commercial availability, customs treatment and cost structure of biotechnology products.

11. Important Judicial Decisions and Case Laws

An important qualification is necessary: Ukrainian reported tax decisions do not necessarily concern biotechnology companies directly. The following cases provide relevant judicial principles from VAT, medical-device and commercial-tax disputes that can be applied by analogy to biotechnology businesses.

Case 1: Supreme Court of Ukraine, Case No. 200/773/20-a, 26 March 2024

Relevant VAT precedent

Subject: VAT taxable base and the determination of market prices.

The dispute concerned the taxpayer's VAT accounting for the supply of its own products.

The taxpayer challenged the tax authority's approach to determining the market value of the supplied products.

The Supreme Court examined the requirements for establishing the taxable base and the evidence necessary to establish that declared prices were inconsistent with market prices.

Legal principle:

Tax authorities must follow the prescribed legal procedure and rely on appropriate evidence when challenging the prices used by a taxpayer.

The court's reasoning is relevant to biotechnology companies selling proprietary biological products, pharmaceutical formulations and specialised research materials.

For example, a tax authority should not arbitrarily substitute its own estimated market price for the declared price of a specialised biotechnology product without complying with the applicable evidentiary and procedural requirements.

Source:

supreme.court.gov.ua

 

Case 2: Supreme Court, Case No. 910/23097/17, 29 June 2021

Important VAT-credit precedent

Subject: Genuine business transactions and VAT input tax credit.

The Grand Chamber of the Supreme Court addressed the legal conditions for recognising VAT input tax credit.

The judgment established that the right to input VAT credit depends on:

Actual acquisition of goods or services.

Use or intended use in taxable business activities.

Properly prepared primary accounting documents.

Accurate information about the substance and volume of the transaction.

Application to biotechnology:

Suppose a Ukrainian biotechnology company purchases laboratory reagents from a supplier and claims input VAT credit.

The company should retain:

Purchase agreements.

Tax invoices.

Customs declarations, where relevant.

Delivery documents.

Laboratory inventory records.

Evidence of actual receipt.

Evidence of business use.

A tax invoice alone does not establish that a transaction genuinely occurred.

Source:

supreme.court.gov.ua

 

Case 3: Supreme Court, DTEK Pavlohradugol Case, 2018

Subject: Documentary proof of VAT input tax credit.

In its judgment reported on 27 April 2018, the Supreme Court considered whether business transactions had been adequately documented for VAT-credit purposes.

The Court emphasised that actual movement of assets and properly prepared primary documents are essential.

Transport documents were relevant when assessed together with other evidence.

Application to biotechnology:

A biotechnology company importing biological samples, laboratory instruments or pharmaceutical ingredients must be able to establish the actual movement and receipt of the goods.

Merely issuing invoices or recording a transaction in accounting records is insufficient if the underlying transaction did not occur.

Legal significance: Scientific and commercial documentation should be consistent with the company's accounting and tax records.

Source:

ВС

 

Case 4: Supreme Court, Commercial Cassation Court, Case No. 916/2438/25, 23 June 2026

Recent medical-device precedent

Subject: VAT exemption for medical devices and their designated purpose.

The dispute concerned the supply of artificial lung ventilation equipment to a hospital.

The question was whether the equipment qualified for a particular VAT exemption under the Tax Code.

The Supreme Court held that the exemption required the simultaneous satisfaction of the applicable statutory conditions.

These included:

The relevant inclusion of the medical devices in the prescribed list.

Supply for the relevant institutional or beneficiary use.

The specified purpose of providing medical assistance to the legally defined category of persons.

The mere purchase of equipment by a hospital was insufficient.

Application to biotechnology:

This decision is important for manufacturers and suppliers of:

Artificial organs.

Biotechnological medical devices.

Ventilation systems.

Advanced diagnostic equipment.

Specialised medical technology.

A company claiming a preferential VAT treatment must demonstrate that all applicable legal conditions are satisfied.

Legal significance: The intended purpose and supporting procurement documentation can be decisive in determining VAT eligibility.

Source:

court.gov.ua

 

Case 5: Supreme Court, Commercial Cassation Court, Case No. 922/2115/19, 3 June 2022

Subject: Genuine transactions and primary accounting documentation.

The Supreme Court considered the relationship between tax invoices, accounting documents and the actual performance of business transactions.

The judgment referred to earlier Supreme Court and Grand Chamber decisions, including the principle that a tax invoice does not independently prove that the underlying transaction actually occurred.

Application to biotechnology:

A biotechnology enterprise cannot rely exclusively on invoices for claimed research expenditure.

For instance, payments to a foreign laboratory should be supported by:

A research-services agreement.

Research protocols.

Laboratory reports.

Deliverables.

Payment records.

Evidence of the actual services performed.

Source:

supreme.court.gov.ua

 

Judicial principles emerging from these cases

Judicial principleRelevance to biotechnology
Actual transactions must be establishedResearch purchases and supplies
Primary documents must be accurateLaboratory and clinical-trial expenses
VAT credit requires statutory conditionsImported reagents and equipment
Special VAT exemptions require proofMedical biotechnology devices
Taxable value must be determined lawfullyPharmaceutical product pricing
Contractual labels alone are insufficientResearch grants and licensing

These decisions are analogous tax precedents, not a collection of biotechnology-specific judgments. Their application depends on the facts and the particular statutory provision in dispute.

12. Biotechnology Tax Incentives and Innovation Policies

Ukraine has legal mechanisms intended to encourage investment, innovation and scientific development. However, biotechnology companies must distinguish between general investment support and specific tax exemptions.

A. Investment incentives

The Law on State Support for Investment Projects with Significant Investments provides a framework for supporting qualifying investment projects.

Potentially relevant biotechnology projects include:

Pharmaceutical manufacturing facilities.

Large-scale vaccine production.

Biotechnology research infrastructure.

Advanced medical manufacturing.

Industrial biological production.

Eligibility depends on the statutory investment thresholds, project characteristics and other legal conditions.

B. Innovation and research infrastructure

Scientific institutions and research organisations may receive funding through government and international programmes.

The tax consequences depend on their legal status, funding structure and applicable statutory provisions.

C. Diia City regime

Ukraine's Diia City is another potentially relevant framework.

A biotechnology company may qualify if it satisfies the applicable requirements, including those concerning permitted activities and resident status.

However, biotechnology research or pharmaceutical manufacturing alone does not automatically qualify an enterprise for Diia City tax treatment.

13. Tax Administration, Audits and Penalties

The State Tax Service of Ukraine administers tax compliance.

Biotechnology companies may face tax inspections involving:

Corporate income tax calculations.

VAT declarations.

Import VAT.

Customs valuation.

Royalty payments.

Research expenditure.

Employee remuneration.

Transfer pricing.

Tax exemptions and incentives.

A. Documentation requirements

A biotechnology company should maintain:

Financial statements.

Tax invoices.

Research and development agreements.

Laboratory expenditure records.

Clinical-trial contracts.

Patent and licensing agreements.

Customs declarations.

Payroll documentation.

Grant agreements.

Evidence of the actual delivery of services and goods.

B. Tax disputes

If the tax authority issues an additional tax assessment, a company may challenge it through the administrative appeal procedure or judicial proceedings.

The dispute may concern:

Incorrect VAT classification.

Rejection of input tax credits.

Disallowed research expenditure.

Disputed customs valuation.

Improper application of tax exemptions.

Transfer-pricing adjustments.

Tax penalties.

C. Evidentiary importance

Biotechnology taxation requires more than conventional accounting records.

For example, a laboratory claiming expenditure on a clinical trial may need to establish that the services were actually performed, that the expenditure was commercially justified and that the relevant documents correspond to the underlying scientific activity.

14. European Union Integration and Biotechnology Taxation

Ukraine's European integration has significant implications for biotechnology businesses.

Relevant European regulatory frameworks include:

EU VAT legislation.

EU pharmaceutical regulation.

EU medical-device regulation.

EU GMO regulation.

EU customs legislation.

International tax cooperation standards.

Ukraine's GMO Law No. 3339-IX represents an important step towards harmonisation with European regulatory approaches.

However, regulatory harmonisation does not mean that every EU tax exemption automatically applies in Ukraine.

Ukrainian biotechnology businesses must follow Ukrainian tax legislation while taking account of applicable international agreements and European regulatory requirements.

15. Practical Examples

The following hypothetical examples illustrate how the legal framework operates.

Example 1: Ukrainian vaccine manufacturer

A Ukrainian company manufactures a registered biotechnology vaccine.

Corporate profits are generally subject to 18% corporate income tax.

Qualifying supplies may attract 7% VAT.

Production equipment is subject to the applicable depreciation rules.

Imports may attract customs duties and import VAT, subject to exemptions.

Example 2: Biotechnology research startup

A startup develops genetic diagnostic technology.

Research expenditure is accounted for under applicable tax rules.

Ordinary consultancy services generally attract 20% VAT.

Grant income must be classified according to its legal character.

Patent licensing income must be treated under applicable intellectual property and tax rules.

Example 3: Foreign biotechnology licensing

A Ukrainian company receives a licence from a German pharmaceutical company.

The transaction may involve:

Royalty withholding tax.

Double-taxation treaty relief.

VAT place-of-supply rules.

Transfer-pricing compliance.

Corporate income tax consequences.

Example 4: Imported laboratory equipment

A Ukrainian university imports DNA sequencing equipment.

The applicable customs treatment depends on the tariff classification, customs value, origin and any specific statutory exemption.

The fact that the equipment is intended for scientific research does not, by itself, establish a customs-duty or VAT exemption.

16. Major Legal Challenges in Ukrainian Biotechnology Taxation

Legal challengePrincipal concern
Research expenditureDetermining allowable tax treatment
Pharmaceutical VATEstablishing eligibility for 7% VAT
Clinical trialsDistinguishing medicines from research services
Patent licensingCorrect classification of royalties
Imported equipmentCustoms valuation and exemptions
GMO materialsRegulatory authorisation and customs compliance
Foreign grantsTax classification and reporting
Transfer pricingValuation of unique biotechnology technologies
Tax auditsEstablishing genuine commercial transactions
Medical devicesProving eligibility for preferential VAT treatment

17. Conclusion

Biotechnology taxation law in Ukraine is an interconnected system of corporate taxation, VAT, customs duties, intellectual property taxation, employment taxation, international tax rules and innovation-related legislation.

The Tax Code of Ukraine remains the principal legal instrument governing the taxation of biotechnology enterprises.

Three issues are particularly important:

1. Pharmaceutical taxation: Qualifying medicines and medical devices may benefit from the reduced 7% VAT rate, subject to registration, authorisation and other statutory conditions.

2. Research and innovation taxation: Research expenditure, grants, licensing arrangements and investment support must be classified according to their actual legal and economic character.

3. Regulatory and tax compliance: Biotechnology enterprises must coordinate tax compliance with GMO legislation, pharmaceutical regulation, customs procedures and international business requirements.

The Supreme Court's decisions in Cases Nos. 200/773/20-a, 910/23097/17 and 916/2438/25 demonstrate the importance of lawful tax valuation, genuine business transactions and compliance with the specific conditions for VAT exemptions.

Ultimately, Ukraine's biotechnology taxation framework seeks to apply general tax principles to a scientifically complex and increasingly international commercial sector. The development of clearer innovation incentives and consistent tax administration will remain important for the growth of Ukraine's biotechnology industry.

18. Important Legal Sources and Further Reading

Law No. 3339-IX – State Regulation of Genetic Engineering Activities.

State Tax Service – VAT treatment of medicines and medical devices.

Supreme Court – Case No. 200/773/20-a.

Supreme Court – Case No. 922/2115/19 and related VAT principles.

Supreme Court – Case No. 916/2438/25.

Supreme Court – VAT input tax credit and primary documents.

Ukrainian Government – GMO registration procedure.

Academic note: This is a general legal research overview, not an individual tax opinion. For an actual transaction, the current consolidated Ukrainian Tax Code, applicable treaty provisions and relevant implementing regulations should be checked as of the transaction date.

LawGratis provides pro bono legal aid and resources to empower communities. Join us in making justice reachable for everyone! Follow our community on Instagram, YouTube, Facebook, and LinkedIn.

LEAVE A COMMENT